A multicentre, retrospective study assessing outcomes for patients with inflammatory bowel disease (IBD).and discontinuation of biologic therapy due to primary vs secondary loss of response and then treated with Ustekinumab
Latest Information Update: 22 Dec 2021
At a glance
- Drugs Ustekinumab (Primary)
- Indications Crohn's disease; Inflammatory bowel diseases
- Focus Therapeutic Use
- 22 Dec 2021 New trial record